The Inflation Reduction Act (IRA), passed in 2022, made changes to the way drugs are covered and reimbursed in Medicare.

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Rybelsus (semaglutide) is a brand-name prescription medication that ... If a person has an Original Medicare plan and Part D, they will pay a separate monthly premium for Part D in addition to their ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

THEY'RE ADVERTISED AS OZEMPIC OR WEGOVY. 12;40;15;00 THE GENERIC NAME IS SEMAGLUTIDE, THESE ARE IN A CLASS OF MEDICATIONS ...

One recent development could pave the way for lower costs. Semaglutide was named as one of 15 drugs up for Medicare price negotiations, as set up by the Inflation Reduction Act. (This will include ...

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

Compounded semaglutide is typically cheaper than branded ... In November, the Biden administration proposed a new rule to expand Medicare and Medicaid coverage to include GLP-1s for weight loss ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated prices for Ozempic, Wegovy, and Rybelsus will be. In Medicare's negotiations ...

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular semaglutide medicines as one of the 15 additional drugs covered under ...